的基础上开发的肺炎球菌结合疫苗的ppt课件.pptVIP

Basis for Developing a Pneumococcal Conjugate Vaccine for Adults;Summary;;Because there are limitations of 23vPs vaccine;Cases;;Pneumococcal Conjugate Offers Additional Benefits over Ps Vaccine;Randomized Trial in Na?ve Elderly 70+ years of age (Germany);7vPnC N = 110; 23vPs N = 104-107 * statistically significant;Immunogenicity of Prevnar vs 23vPs after Dose 1 – OPA;Randomized Trial in Na?ve Elderly Does Prior Ps affect the response to PnC?;Prior 23vPs Blunts the Response to Subsequent Prevnar (Hyporesponsiveness);Prior Prevnar Does Not Blunt the Response to a 2nd Dose of Prevnar;PnC;Prior Prevnar Does Not Blunt the Response to Subsequent 23vPs – ELISA Antibody;Would Ps induced hyporesponsiveness improve with longer interval?;23vPS reduces the response to subsequent doses of 23vPS (Torling, Vaccine 2003);Prevnar Immunogenicity in the Elderly support the following;;Estimated Impact on Invasive Pneumococcal Disease-Simplifying Assumptions:;Impact of Extending The Age Range of Protection;Impact of Extending The Age Range of Protection;13vPnC + 23vPs;This is Conservative Estimate of Public Health Impact of PnC ;;Historically 2 Approaches Used for Licensure of Polysaccharide-based Vaccines;Proposal Licensing Criteria for Adult Pneumococcal Conjugate;Scientific Basis for Proving Efficacy Based on Serologic Studies;Efficacy of 23v Ps Vaccine for IPD has been established;Rationale for OPA as a Surrogate for Clinical Efficacy in Adults;ELISA and OPA of Infants (140-1) after 3 Doses of Prevnar (7 mos);Efficacy of Prevnar in Infants by Serotype;Low OPA explains why elderly are at risk of IPD Despite Good ELISA Antibody;Pneumococcal Antibody Levels in Unimmunized Elderly vs Infants after Prevnar;;;OPA and ELISA Responses to Pneumococcal Conjugate Vaccine in Elderly vs Infants;OPA and ELISA Responses to Pneumococcal Conjugate Vaccine in Elderly vs Infants;Proposed Licensing Criteria for Adult Pneumococcal Conjugate;;Constraints on Performing Pneumococcal Conjugate Vaccine